التداخل بين ديسونيد وأوستيكينوماب

Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids.

In trials in subjects with Crohn's disease (CD-1 and CD-2) and ulcerative colitis (UC-1), immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohn's disease and ulcerative colitis subjects, respectively.